Immunome (IMNM) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary

Strategic program updates and pipeline outlook

• Preparing for the commercial launch of varegacestat, a gamma-secretase inhibitor, with NDA submitted and FDA review status expected by month-end; launch preparations include building commercial and medical affairs teams and engaging with key opinion leaders.

• Full phase III RINGSIDE data for varegacestat in desmoid tumors showed a 56% objective response rate, 83% median tumor volume reduction, and rapid, clinically meaningful pain reduction, with a favorable safety profile and managed ovarian toxicity.

• Commercial readiness efforts include assembling an experienced team, strong engagement with physicians, and positive feedback from key opinion leaders; sales force to be onboarded closer to PDUFA date.

• Initial payer discussions acknowledge the potential for premium pricing due to superior efficacy, but final pricing and peak sales estimates are pending further analysis; market opportunity seen in expanding gamma-secretase inhibitor use beyond current 10% penetration.

• Competitive positioning highlights once-daily oral dosing and rapid pain relief as key differentiators versus competitors, with ongoing monitoring of emerging assets targeting adjacent pathways.

ADC platform development and differentiation

• IM-1021, a ROR1-targeted ADC, will have its first major data set released in the second half of the year, with objective responses already observed in B-cell lymphoma; data will inform dose, schedule, and future directions.

• Three additional solid tumor ADC programs are advancing, all using the proprietary TOPO1 inhibitor HC74; IM-1617 has IND clearance, with two more INDs planned this year.

• Platform differentiation centers on novel target selection, HC74’s resistance to efflux pumps, strong bystander effect, and streamlined linker chemistry, aiming to overcome resistance and improve efficacy in heterogeneous tumors.

• Learnings from Seagen emphasize the importance of optimizing all ADC components and clinical strategy, with a focus on unmet needs rather than crowded targets.

• IM-3050, a FAP-targeted radioligand therapy, is in phase I, leveraging a beta emitter for broad tumor coverage and aiming for improved tumor retention and efficacy.

Financial position and business development

• Cash runway extends into 2028, supporting commercial launch and advancement of all pipeline programs, including potential expansion of IM-1021 studies.

• Business development strategy is selective, prioritizing partnerships that add strategic value rather than short-term financial gains; ongoing interest from investors and pharma in ADC platform.